CRISPR Therapeutics — Biomedical Watch V2

Traitements3programmes

Essais2liés

Publications0liées

SourceDBlocale

Traitements

3

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
CTX112This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with refractory autoimmune diseases, including active systemic lupus erythematosus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM).	Lupus, Myopathies, SEP	Phase 1	Remyélinisation	United States, Germany, Spain	À vérifier
CTX112This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with refractory autoimmune diseases, including active systemic lupus erythematosus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM).	Lupus	Phase 1	Remyélinisation	United States, Germany, Spain	À vérifier
CTX112This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with refractory autoimmune diseases, including active systemic lupus erythematosus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM).	SEP	Phase 1/2	Remyélinisation		À vérifier

Essais cliniques

2

Molécule	Indication / population	Phase	NCT	Titre	Statut
CTX112	SEP	Phase 1/2	NCT07804004	CRSP-AID-502 — A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease	NOT_YET_RECRUITING
CTX112	Lupus	Phase 1	NCT06925542	A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease	RECRUITING

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.